X4 PHARMACEUTICALS XFOR 深 沪
已收盘 08-15 16:00:00 美东时间
2.85
-0.290
-9.24%
华盛通- 最 高3.11
- 今 开2.89
- 成交量 185.08万股
- 最 低 2.66
- 昨 收 3.14
- 总市值 3251.39万
- 52周最高 26.829
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 1.35
- 委 比 -53.38%
- 总股本 1140.84万
- 历史最高 717.90
- 量 比 0.05
- 振 幅 14.33%
- 历史最低 2.66
- 每 手 1
- 风险率 7.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
X4 Pharmaceuticals completed a $85 million private placement of shares and warrants, up from the initial $60 million target, to include an investor with a pre-existing investment right. The financing was led by Coastlands Capital, supported by existing and new life sciences investors. Proceeds will fund the continued development of mavorixafor for chronic neutropenia and WHIM syndrome commercialization.
08-13 11:00
X4 Pharmaceuticals secures $60M PIPE financing
X4 Pharmaceuticals (NASDAQ:XFOR) has entered into a $60 million PIPE financing deal, expected to close around August 13, 2025, pending customary conditions. The company will issue 11,040,776 shares at...
08-12 21:49
X4 Pharmaceuticals Announced Private Placement In Public Equity Financing Of Approximately $60M
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise AssociatesNewly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as
08-12 19:14
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
X4 Pharmaceuticals announced a $60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences, and NEA. The company also appointed Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as CFO, all former CTI BioPharma executives. New leadership aims to unlock the commercial potential of mavorixafor. Proceeds will support further development and commercialization efforts.
08-12 11:00
Mach42™ Unveils Breakthrough AI Solution for Analog Circuit Analysis
Advancing IP Reuse with an AI-powered Companion to SPICE Simulation Key Highlights The Mach42 platform enables rapid validation of design performance across varying spec conditions, supporti...
08-04 18:00
中国汽研与IEEE ITSS签署合作备忘录
近日，中国汽研与IEEE ITSS/SC智能交通系统学会签署合作备忘录。中国汽研副总经理王锐、IEEE ITSS/SC标准主席Meng Lu博士出席签约仪式。...
07-15 17:41
X4 Pharmaceuticals Completes Key Study on Mavorixafor’s Drug Interaction Potential
X4 Pharmaceuticals (($XFOR)) announced an update on their ongoing clinical stud...
07-02 00:09
X4 Pharmaceuticals Enters Purchase Agreement With Lincoln Park; Can Sell Up To $40M In Stock
https://www.sec.gov/ix?doc=/Archives/edgar/data/1501697/000162828025032627/xfor-20250623.htm
06-24 04:41
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
X4 Pharmaceuticals announced positive results from its Phase 2 trial of mavorixafor for treating chronic neutropenia. The study showed sustained increases in neutrophils and reduced need for G-CSF in patients, supporting the ongoing Phase 3 trial. Mavorixafor is a potential oral therapy for chronic neutropenia, addressing a rare condition with limited treatment options. The trial's success strengthens confidence in the upcoming Phase 3 results, e...
06-16 12:00
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA
X4 Pharmaceuticals announced that the U.S. FDA has granted Fast Track designation to mavorixafor, an oral CXCR4 antagonist, for the treatment of chronic neutropenia (CN). The company is conducting a global Phase 3 trial evaluating mavorixafor in primary CN conditions. Mavorixafor previously received Fast Track designation for WHIM syndrome, which was approved in April 2024. The company aims to complete Phase 3 enrollment by late 2025 and expects ...
06-10 12:00
